Iptacopan – Talk Bio

Actionable Insights Powered by AI

Novartis Reveals Sustained Efficacy and Safety of Fabhalta in Patients Switching from Anti-C5 Therapies for Paroxysmal Nocturnal Hemoglobinuria (PNH)

5 months ago talkbio0Tagged anti-C5, Avoidance, Blood Transfusion, Effectiveness, Fabhalta, Hemoglobin improvement, Iptacopan, Paroxysmal, Paroxysmal nocturnal hemoglobinuria, PNH, Safety, Switching therapies

Fabhalta (iptacopan), Paroxysmal Nocturnal Hemoglobinuria (PNH), Anti-C5 therapies, Efficacy and safety, Switching therapies, Hemoglobin improvement, Transfusion avoidance

Novartis’ Fabhalta (Iptacopan) Receives FDA Priority Review for IgA Nephropathy (IgAN) Treatment

1 year ago talkbio0Tagged Fabhalta, IGA Glomerulonephritis, Iptacopan, Novartis, Phase 3, Priority Review, United States Food and Drug Administration

Novartis, Fabhalta, Iptacopan, IgA Nephropathy (IgAN), FDA Priority Review, Phase 3 Data